找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Druggable Lipid Signaling Pathways; Yasuyuki Kihara Book 2020 Springer Nature Switzerland AG 2020 lipids.GPCR.drug discovery.disease.trans

[復制鏈接]
查看: 49802|回復: 44
樓主
發(fā)表于 2025-3-21 18:52:45 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Druggable Lipid Signaling Pathways
編輯Yasuyuki Kihara
視頻videohttp://file.papertrans.cn/284/283174/283174.mp4
概述Revisits historical achievements of lipid research and updates the latest understanding of lipid functions.Inspires new perspectives on discovering drugs in lipid signaling pathways.Written by the nex
叢書名稱Advances in Experimental Medicine and Biology
圖書封面Titlebook: Druggable Lipid Signaling Pathways;  Yasuyuki Kihara Book 2020 Springer Nature Switzerland AG 2020 lipids.GPCR.drug discovery.disease.trans
描述.Lipids are responsible not just for constituting cellular membrane but also for storing energy, transducing signaling, and modifying proteins. Bioactive lipids, or lipid mediators, transduce signaling as intracellular messenger like phosphoinoitides, and also regulate cell-cell communication through G protein-coupled receptors (GPCRs) that are potentially valuable drug targets in many diseases. Until now, about 40 GPCRs within ~300 rhodopsin-like (class A) GPCRs, are identified as lipid GPCRs. Advances of lipid research have enabled to develop novel small molecules targeting lipid GPCRs for several diseases. Most notably, fingolimod (FTY720), a sphingosine 1-phosphate (S1P) receptor modulator, became the first FDA-approved medicine as an orally bioavailable drug for treating relapsing forms of multiple sclerosis (MS). In addition to fingolimod, other drugs targeting lipid GPCRs had been developed such as latanoprost (prostaglandin F2a analogue, used for ocular hypertension and glaucoma), epoprostenol and treprostinil (prostaglandin I2 analogue, used for pulmonary arterial hypertension), montelukast and pranlukast (cysteinyl leukotriene receptor antagonist, used for asthma and alle
出版日期Book 2020
關鍵詞lipids; GPCR; drug discovery; disease; translational research
版次1
doihttps://doi.org/10.1007/978-3-030-50621-6
isbn_softcover978-3-030-50623-0
isbn_ebook978-3-030-50621-6Series ISSN 0065-2598 Series E-ISSN 2214-8019
issn_series 0065-2598
copyrightSpringer Nature Switzerland AG 2020
The information of publication is updating

書目名稱Druggable Lipid Signaling Pathways影響因子(影響力)




書目名稱Druggable Lipid Signaling Pathways影響因子(影響力)學科排名




書目名稱Druggable Lipid Signaling Pathways網(wǎng)絡公開度




書目名稱Druggable Lipid Signaling Pathways網(wǎng)絡公開度學科排名




書目名稱Druggable Lipid Signaling Pathways被引頻次




書目名稱Druggable Lipid Signaling Pathways被引頻次學科排名




書目名稱Druggable Lipid Signaling Pathways年度引用




書目名稱Druggable Lipid Signaling Pathways年度引用學科排名




書目名稱Druggable Lipid Signaling Pathways讀者反饋




書目名稱Druggable Lipid Signaling Pathways讀者反饋學科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權限
沙發(fā)
發(fā)表于 2025-3-21 21:24:25 | 只看該作者
Biosynthetic Enzymes of Membrane Glycerophospholipid Diversity as Therapeutic Targets for Drug Devecorporate fatty chains into lysophospholipids to affect the fatty acid composition of membrane glycerophospholipids. Lysophosphatidic acid acyltransferases (LPAATs) of the 1-acylglycerol-3-phosphate .-acyltransferase (AGPAT) family incorporate fatty chains into phosphatidic acid during the . glycero
板凳
發(fā)表于 2025-3-22 04:08:12 | 只看該作者
Druggable Prostanoid Pathway, (AA). Protanoids control numerous physiological and pathological processes. Cyclooxygenase (COX) is a rate-limiting enzyme involved in the conversion of AA into prostanoids. There are two COX isozymes: the constitutive COX-1 and the inducible COX-2. COX-1 and COX-2 have similar structures, catalyti
地板
發(fā)表于 2025-3-22 08:21:02 | 只看該作者
Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolicto exerting potent proinflammatory effects. Therefore,?LTs are essential elements in the development and maintenance of different chronic diseases, such as asthma, arthritis, and atherosclerosis. Due to the pleiotropic effects of LTs in the pathogenesis of inflammatory diseases, studies are needed t
5#
發(fā)表于 2025-3-22 10:37:52 | 只看該作者
6#
發(fā)表于 2025-3-22 15:01:29 | 只看該作者
7#
發(fā)表于 2025-3-22 18:36:27 | 只看該作者
Druggable Lysophospholipid Signaling Pathways,lmost every major organ system. In this review we discuss LPA signaling pathways as emerging drug targets for multiple conditions relevant to human health and disease. LPA signals through the six G protein-coupled receptors LPA., and several of these receptors along with the LPA-producing enzyme inc
8#
發(fā)表于 2025-3-22 22:15:41 | 只看該作者
9#
發(fā)表于 2025-3-23 03:55:31 | 只看該作者
10#
發(fā)表于 2025-3-23 06:05:29 | 只看該作者
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 22:50
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
鹿泉市| 稻城县| 三明市| 康保县| 通辽市| 仲巴县| 兴山县| 白玉县| 上杭县| 尼玛县| 舒城县| 惠水县| 南投市| 防城港市| 宝应县| 抚宁县| 开平市| 屏东县| 上林县| 普洱| 舞钢市| 司法| 颍上县| 得荣县| 城口县| 榕江县| 左云县| 常山县| 凤台县| 岳阳市| 中江县| 尼玛县| 突泉县| 五大连池市| 万安县| 广德县| 佳木斯市| 乳山市| 井研县| 大英县| 蒙山县|